E. Carcereny Costa

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

K. Syrigos, K. O'Byrne, Keunchil Park, 2019, The New England journal of medicine.

OA01.07 A Phase II Study of the Oral Selective AXL Inhibitor Bemcentinib with Pembrolizumab in Patients with Advanced NSCLC

E. Schmidt, E. Felip, H. Gabra, 2021 .

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).

P. Jänne, S. Gettinger, F. Shepherd, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study

H. Groen, H. Wakelee, E. Smit, 2020, JTO clinical and research reports.